1	Three	_	CD	_	_	4	NMOD	_	_
2	leading	_	VBG	_	_	4	NMOD	_	_
3	drug	_	NN	_	_	4	NMOD	_	_
4	companies	_	NNS	_	_	5	SBJ	_	_
5	reported	_	VBD	_	_	0	ROOT	_	_
6	robust	_	JJ	_	_	8	NMOD	_	_
7	third-quarter	_	NN	_	_	8	NMOD	_	_
8	earnings	_	NNS	_	_	5	OBJ	_	_
9	,	_	,	_	_	8	P	_	_
10	bolstered	_	VBN	_	_	8	APPO	_	_
11	by	_	IN	_	_	10	LGS	_	_
12	strong	_	JJ	_	_	13	NMOD	_	_
13	sales	_	NNS	_	_	11	PMOD	_	_
14	of	_	IN	_	_	13	NMOD	_	_
15	newer	_	JJR	_	_	19	NMOD	_	_
16	,	_	,	_	_	19	P	_	_
17	big-selling	_	JJ	_	_	19	NMOD	_	_
18	prescriptions	_	NNS	_	_	19	NMOD	_	_
19	drugs	_	NNS	_	_	14	PMOD	_	_
20	that	_	WDT	_	_	21	SBJ	_	_
21	provide	_	VBP	_	_	19	NMOD	_	_
22	hefty	_	JJ	_	_	24	NMOD	_	_
23	profit	_	NN	_	_	24	NMOD	_	_
24	margins	_	NNS	_	_	21	OBJ	_	_
25	.	_	.	_	_	5	P	_	_

1	Merck	_	NNP	_	_	4	SBJ	_	_
2	&	_	CC	_	_	1	COORD	_	_
3	Co.	_	NNP	_	_	2	CONJ	_	_
4	reported	_	VBD	_	_	0	ROOT	_	_
5	a	_	DT	_	_	8	NMOD	_	_
6	25	_	CD	_	_	7	AMOD	_	_
7	%	_	NN	_	_	8	NMOD	_	_
8	increase	_	NN	_	_	4	OBJ	_	_
9	in	_	IN	_	_	8	LOC	_	_
10	earnings	_	NNS	_	_	9	PMOD	_	_
11	;	_	:	_	_	4	P	_	_
12	Warner-Lambert	_	NNP	_	_	13	NAME	_	_
13	Co.	_	NNP	_	_	15	NMOD	_	_
14	's	_	POS	_	_	13	SUFFIX	_	_
15	profit	_	NN	_	_	16	SBJ	_	_
16	rose	_	VBD	_	_	4	COORD	_	_
17	22	_	CD	_	_	18	NMOD	_	_
18	%	_	NN	_	_	16	EXT	_	_
19	and	_	CC	_	_	16	COORD	_	_
20	Eli	_	NNP	_	_	21	NAME	_	_
21	Lilly	_	NNP	_	_	26	NMOD	_	_
22	&	_	CC	_	_	21	COORD	_	_
23	Co.	_	NNP	_	_	22	CONJ	_	_
24	's	_	POS	_	_	23	SUFFIX	_	_
25	net	_	JJ	_	_	26	NMOD	_	_
26	income	_	NN	_	_	27	SBJ	_	_
27	rose	_	VBD	_	_	19	CONJ	_	_
28	24	_	CD	_	_	29	NMOD	_	_
29	%	_	NN	_	_	27	EXT	_	_
30	.	_	.	_	_	4	P	_	_

1	The	_	DT	_	_	2	NMOD	_	_
2	results	_	NNS	_	_	3	SBJ	_	_
3	were	_	VBD	_	_	0	ROOT	_	_
4	in	_	IN	_	_	3	PRD	_	_
5	line	_	NN	_	_	4	PMOD	_	_
6	with	_	IN	_	_	5	NMOD	_	_
7	analysts	_	NNS	_	_	9	NMOD	_	_
8	'	_	POS	_	_	7	SUFFIX	_	_
9	expectations	_	NNS	_	_	6	PMOD	_	_
10	.	_	.	_	_	3	P	_	_

1	Merck	_	NNP	_	_	0	ROOT	_	_
2	&	_	CC	_	_	1	COORD	_	_
3	Co	_	NNP	_	_	2	CONJ	_	_
4	.	_	.	_	_	3	P	_	_

1	Merck	_	NNP	_	_	7	SBJ	_	_
2	,	_	,	_	_	1	P	_	_
3	Rahway	_	NNP	_	_	1	LOC	_	_
4	,	_	,	_	_	3	P	_	_
5	N.J.	_	NNP	_	_	3	APPO	_	_
6	,	_	,	_	_	1	P	_	_
7	continued	_	VBD	_	_	0	ROOT	_	_
8	to	_	TO	_	_	7	OPRD	_	_
9	lead	_	VB	_	_	8	IM	_	_
10	the	_	DT	_	_	11	NMOD	_	_
11	industry	_	NN	_	_	9	OBJ	_	_
12	with	_	IN	_	_	9	ADV	_	_
13	a	_	DT	_	_	16	NMOD	_	_
14	strong	_	JJ	_	_	16	NMOD	_	_
15	sales	_	NNS	_	_	16	NMOD	_	_
16	performance	_	NN	_	_	12	PMOD	_	_
17	in	_	IN	_	_	16	LOC	_	_
18	the	_	DT	_	_	19	NMOD	_	_
19	human	_	NN	_	_	17	PMOD	_	_
20	and	_	CC	_	_	19	COORD	_	_
21	animal	_	NN	_	_	23	NMOD	_	_
22	health-products	_	NNS	_	_	23	NMOD	_	_
23	segment	_	NN	_	_	20	CONJ	_	_
24	.	_	.	_	_	7	P	_	_

1	A	_	DT	_	_	4	NMOD	_	_
2	stronger	_	JJR	_	_	4	NMOD	_	_
3	U.S.	_	NNP	_	_	4	NMOD	_	_
4	dollar	_	NN	_	_	5	SBJ	_	_
5	reduced	_	VBD	_	_	0	ROOT	_	_
6	third-quarter	_	NN	_	_	5	OBJ	_	_
7	and	_	CC	_	_	6	COORD	_	_
8	first-nine-month	_	JJ	_	_	10	NMOD	_	_
9	sales	_	NNS	_	_	10	NMOD	_	_
10	growth	_	NN	_	_	7	CONJ	_	_
11	2	_	CD	_	_	12	DEP	_	_
12	%	_	NN	_	_	5	EXT	_	_
13	and	_	CC	_	_	12	COORD	_	_
14	3	_	CD	_	_	13	CONJ	_	_
15	%	_	NN	_	_	14	COORD	_	_
16	,	_	,	_	_	12	P	_	_
17	respectively	_	RB	_	_	12	NMOD	_	_
18	.	_	.	_	_	5	P	_	_

1	International	_	JJ	_	_	2	NMOD	_	_
2	sales	_	NNS	_	_	3	SBJ	_	_
3	accounted	_	VBD	_	_	0	ROOT	_	_
4	for	_	IN	_	_	3	ADV	_	_
5	47	_	CD	_	_	6	NMOD	_	_
6	%	_	NN	_	_	4	PMOD	_	_
7	of	_	IN	_	_	6	NMOD	_	_
8	total	_	JJ	_	_	10	NMOD	_	_
9	company	_	NN	_	_	10	NMOD	_	_
10	sales	_	NNS	_	_	7	PMOD	_	_
11	for	_	IN	_	_	10	NMOD	_	_
12	the	_	DT	_	_	14	NMOD	_	_
13	nine	_	CD	_	_	14	NMOD	_	_
14	months	_	NNS	_	_	11	PMOD	_	_
15	,	_	,	_	_	3	P	_	_
16	compared	_	VBN	_	_	3	ADV	_	_
17	with	_	IN	_	_	16	PMOD	_	_
18	50	_	CD	_	_	19	NMOD	_	_
19	%	_	NN	_	_	17	PMOD	_	_
20	a	_	DT	_	_	21	NMOD	_	_
21	year	_	NN	_	_	22	AMOD	_	_
22	earlier	_	RBR	_	_	17	TMP	_	_
23	.	_	.	_	_	3	P	_	_

1	Sales	_	NNS	_	_	5	SBJ	_	_
2	for	_	IN	_	_	1	NMOD	_	_
3	the	_	DT	_	_	4	NMOD	_	_
4	quarter	_	NN	_	_	2	PMOD	_	_
5	rose	_	VBD	_	_	0	ROOT	_	_
6	to	_	TO	_	_	5	DIR	_	_
7	$	_	$	_	_	6	PMOD	_	_
8	1.63	_	CD	_	_	7	DEP	_	_
9	billion	_	CD	_	_	7	DEP	_	_
10	from	_	IN	_	_	5	DIR	_	_
11	$	_	$	_	_	10	PMOD	_	_
12	1.47	_	CD	_	_	11	DEP	_	_
13	billion	_	CD	_	_	11	DEP	_	_
14	.	_	.	_	_	5	P	_	_

1	Mevacor	_	NNP	_	_	9	SBJ	_	_
2	,	_	,	_	_	1	P	_	_
3	Merck	_	NNP	_	_	7	NMOD	_	_
4	's	_	POS	_	_	3	SUFFIX	_	_
5	new	_	JJ	_	_	7	NMOD	_	_
6	cholesterol-lowering	_	JJ	_	_	7	NMOD	_	_
7	drug	_	NN	_	_	1	APPO	_	_
8	,	_	,	_	_	1	P	_	_
9	had	_	VBD	_	_	31	OBJ	_	_
10	higher	_	JJR	_	_	11	NMOD	_	_
11	sales	_	NNS	_	_	9	OBJ	_	_
12	than	_	IN	_	_	11	NMOD	_	_
13	any	_	DT	_	_	16	NMOD	_	_
14	other	_	JJ	_	_	16	NMOD	_	_
15	prescription	_	NN	_	_	16	NMOD	_	_
16	medicine	_	NN	_	_	17	SBJ	_	_
17	has	_	VBZ	_	_	12	SUB	_	_
18	ever	_	RB	_	_	17	TMP	_	_
19	achieved	_	VBN	_	_	17	VC	_	_
20	in	_	IN	_	_	19	LOC	_	_
21	the	_	DT	_	_	22	NMOD	_	_
22	U.S.	_	NNP	_	_	20	PMOD	_	_
23	in	_	IN	_	_	19	TMP	_	_
24	the	_	DT	_	_	25	NMOD	_	_
25	year	_	NN	_	_	23	PMOD	_	_
26	following	_	VBG	_	_	25	NMOD	_	_
27	introduction	_	NN	_	_	26	PMOD	_	_
28	,	_	,	_	_	31	P	_	_
29	the	_	DT	_	_	30	NMOD	_	_
30	company	_	NN	_	_	31	SBJ	_	_
31	said	_	VBD	_	_	0	ROOT	_	_
32	.	_	.	_	_	31	P	_	_

1	The	_	DT	_	_	2	NMOD	_	_
2	drug	_	NN	_	_	3	SBJ	_	_
3	was	_	VBD	_	_	0	ROOT	_	_
4	introduced	_	VBN	_	_	3	VC	_	_
5	in	_	IN	_	_	4	LOC	_	_
6	West	_	NNP	_	_	7	NAME	_	_
7	Germany	_	NNP	_	_	5	PMOD	_	_
8	this	_	DT	_	_	9	NMOD	_	_
9	year	_	NN	_	_	4	TMP	_	_
10	.	_	.	_	_	3	P	_	_

1	Intense	_	JJ	_	_	2	NMOD	_	_
2	competition	_	NN	_	_	6	SBJ	_	_
3	,	_	,	_	_	6	P	_	_
4	however	_	RB	_	_	6	ADV	_	_
5	,	_	,	_	_	6	P	_	_
6	led	_	VBD	_	_	0	ROOT	_	_
7	to	_	TO	_	_	6	DIR	_	_
8	unit	_	NN	_	_	10	NMOD	_	_
9	sales	_	NNS	_	_	10	NMOD	_	_
10	declines	_	NNS	_	_	7	PMOD	_	_
11	for	_	IN	_	_	10	NMOD	_	_
12	a	_	DT	_	_	13	NMOD	_	_
13	group	_	NN	_	_	11	PMOD	_	_
14	of	_	IN	_	_	13	NMOD	_	_
15	Merck	_	NNP	_	_	18	NMOD	_	_
16	's	_	POS	_	_	15	SUFFIX	_	_
17	established	_	VBN	_	_	18	NMOD	_	_
18	human	_	NN	_	_	14	PMOD	_	_
19	and	_	CC	_	_	18	COORD	_	_
20	animal-health	_	NN	_	_	21	NMOD	_	_
21	products	_	NNS	_	_	19	CONJ	_	_
22	,	_	,	_	_	13	P	_	_
23	including	_	VBG	_	_	13	NMOD	_	_
24	Aldomet	_	NNP	_	_	23	PMOD	_	_
25	and	_	CC	_	_	24	COORD	_	_
26	Indocin	_	NNP	_	_	25	CONJ	_	_
27	.	_	.	_	_	6	P	_	_

1	In	_	IN	_	_	12	LOC	_	_
2	New	_	NNP	_	_	7	NMOD	_	_
3	York	_	NNP	_	_	7	NMOD	_	_
4	Stock	_	NNP	_	_	7	NMOD	_	_
5	Exchange	_	NNP	_	_	7	NMOD	_	_
6	composite	_	JJ	_	_	7	NMOD	_	_
7	trading	_	NN	_	_	1	PMOD	_	_
8	yesterday	_	NN	_	_	12	TMP	_	_
9	,	_	,	_	_	12	P	_	_
10	Merck	_	NN	_	_	11	NMOD	_	_
11	shares	_	NNS	_	_	12	SBJ	_	_
12	closed	_	VBD	_	_	0	ROOT	_	_
13	at	_	IN	_	_	12	ADV	_	_
14	$	_	$	_	_	13	PMOD	_	_
15	75.25	_	CD	_	_	14	NMOD	_	_
16	,	_	,	_	_	12	P	_	_
17	up	_	IN	_	_	12	ADV	_	_
18	50	_	CD	_	_	19	NMOD	_	_
19	cents	_	NNS	_	_	17	AMOD	_	_
20	.	_	.	_	_	12	P	_	_

1	Warner-Lambert	_	NNP	_	_	2	NAME	_	_
2	Co	_	NNP	_	_	0	ROOT	_	_
3	.	_	.	_	_	2	P	_	_

1	Warner-Lambert	_	NNP	_	_	8	SBJ	_	_
2	,	_	,	_	_	1	P	_	_
3	Morris	_	NNP	_	_	4	NAME	_	_
4	Plains	_	NNP	_	_	1	APPO	_	_
5	,	_	,	_	_	4	P	_	_
6	N.J.	_	NNP	_	_	4	APPO	_	_
7	,	_	,	_	_	4	P	_	_
8	reported	_	VBD	_	_	0	ROOT	_	_
9	sales	_	NNS	_	_	8	OBJ	_	_
10	that	_	WDT	_	_	11	SBJ	_	_
11	were	_	VBD	_	_	9	NMOD	_	_
12	a	_	DT	_	_	13	NMOD	_	_
13	record	_	NN	_	_	11	PRD	_	_
14	for	_	IN	_	_	13	NMOD	_	_
15	any	_	DT	_	_	16	NMOD	_	_
16	quarter	_	NN	_	_	14	PMOD	_	_
17	and	_	CC	_	_	13	COORD	_	_
18	the	_	DT	_	_	20	NMOD	_	_
19	eighth	_	JJ	_	_	20	NMOD	_	_
20	quarter	_	NN	_	_	17	CONJ	_	_
21	in	_	IN	_	_	20	NMOD	_	_
22	a	_	DT	_	_	23	NMOD	_	_
23	row	_	NN	_	_	21	PMOD	_	_
24	of	_	IN	_	_	20	NMOD	_	_
25	20	_	CD	_	_	26	DEP	_	_
26	%	_	NN	_	_	31	NMOD	_	_
27	or	_	CC	_	_	26	COORD	_	_
28	more	_	JJR	_	_	27	CONJ	_	_
29	per-share	_	JJ	_	_	31	NMOD	_	_
30	earnings	_	NNS	_	_	31	NMOD	_	_
31	growth	_	NN	_	_	24	PMOD	_	_
32	.	_	.	_	_	8	P	_	_

1	Spurred	_	VBN	_	_	15	ADV	_	_
2	by	_	IN	_	_	1	LGS	_	_
3	growth	_	NN	_	_	2	PMOD	_	_
4	in	_	IN	_	_	3	LOC	_	_
5	world-wide	_	JJ	_	_	6	NMOD	_	_
6	sales	_	NNS	_	_	4	PMOD	_	_
7	of	_	IN	_	_	6	NMOD	_	_
8	the	_	DT	_	_	9	NMOD	_	_
9	company	_	NN	_	_	12	NMOD	_	_
10	's	_	POS	_	_	9	SUFFIX	_	_
11	prescription	_	NN	_	_	12	NMOD	_	_
12	drugs	_	NNS	_	_	7	PMOD	_	_
13	,	_	,	_	_	15	P	_	_
14	Warner-Lambert	_	NNP	_	_	15	SBJ	_	_
15	said	_	VBD	_	_	0	ROOT	_	_
16	1989	_	CD	_	_	17	SBJ	_	_
17	will	_	MD	_	_	15	OBJ	_	_
18	be	_	VB	_	_	17	VC	_	_
19	the	_	DT	_	_	21	NMOD	_	_
20	best	_	JJS	_	_	21	NMOD	_	_
21	year	_	NN	_	_	18	PRD	_	_
22	in	_	IN	_	_	21	TMP	_	_
23	its	_	PRP$	_	_	24	NMOD	_	_
24	history	_	NN	_	_	22	PMOD	_	_
25	,	_	,	_	_	18	P	_	_
26	with	_	IN	_	_	18	ADV	_	_
27	per-share	_	JJ	_	_	28	NMOD	_	_
28	earnings	_	NNS	_	_	29	SBJ	_	_
29	expected	_	VBN	_	_	26	SUB	_	_
30	to	_	TO	_	_	29	OPRD	_	_
31	increase	_	VB	_	_	30	IM	_	_
32	more	_	JJR	_	_	34	DEP	_	_
33	than	_	IN	_	_	34	DEP	_	_
34	20	_	CD	_	_	35	NMOD	_	_
35	%	_	NN	_	_	31	OBJ	_	_
36	to	_	TO	_	_	31	DIR	_	_
37	about	_	IN	_	_	38	DEP	_	_
38	$	_	$	_	_	36	PMOD	_	_
39	6.10	_	CD	_	_	38	DEP	_	_
40	.	_	.	_	_	15	P	_	_

1	Sales	_	NNS	_	_	5	SBJ	_	_
2	for	_	IN	_	_	1	NMOD	_	_
3	the	_	DT	_	_	4	NMOD	_	_
4	quarter	_	NN	_	_	2	PMOD	_	_
5	rose	_	VBD	_	_	0	ROOT	_	_
6	to	_	TO	_	_	5	DIR	_	_
7	$	_	$	_	_	6	PMOD	_	_
8	1.11	_	CD	_	_	7	DEP	_	_
9	billion	_	CD	_	_	7	DEP	_	_
10	from	_	IN	_	_	5	DIR	_	_
11	$	_	$	_	_	10	PMOD	_	_
12	1.03	_	CD	_	_	11	DEP	_	_
13	billion	_	CD	_	_	11	DEP	_	_
14	.	_	.	_	_	5	P	_	_

1	Prescription-drug	_	NN	_	_	3	NMOD	_	_
2	world-wide	_	JJ	_	_	3	NMOD	_	_
3	sales	_	NNS	_	_	4	SBJ	_	_
4	rose	_	VBD	_	_	0	ROOT	_	_
5	9	_	CD	_	_	6	NMOD	_	_
6	%	_	NN	_	_	4	EXT	_	_
7	in	_	IN	_	_	4	TMP	_	_
8	the	_	DT	_	_	9	NMOD	_	_
9	quarter	_	NN	_	_	7	PMOD	_	_
10	to	_	TO	_	_	4	DIR	_	_
11	$	_	$	_	_	10	PMOD	_	_
12	340	_	CD	_	_	11	DEP	_	_
13	million	_	CD	_	_	11	DEP	_	_
14	;	_	:	_	_	4	P	_	_
15	U.S.	_	NNP	_	_	16	NMOD	_	_
16	sales	_	NNS	_	_	17	SBJ	_	_
17	rose	_	VBD	_	_	4	COORD	_	_
18	15	_	CD	_	_	19	NMOD	_	_
19	%	_	NN	_	_	17	EXT	_	_
20	.	_	.	_	_	4	P	_	_

1	The	_	DT	_	_	2	NMOD	_	_
2	segment	_	NN	_	_	4	NMOD	_	_
3	's	_	POS	_	_	2	SUFFIX	_	_
4	growth	_	NN	_	_	5	SBJ	_	_
5	was	_	VBD	_	_	0	ROOT	_	_
6	led	_	VBN	_	_	5	VC	_	_
7	by	_	IN	_	_	6	LGS	_	_
8	sales	_	NNS	_	_	7	PMOD	_	_
9	of	_	IN	_	_	8	NMOD	_	_
10	the	_	DT	_	_	12	NMOD	_	_
11	cardiovascular	_	JJ	_	_	12	NMOD	_	_
12	drugs	_	NNS	_	_	9	PMOD	_	_
13	Lopid	_	NNP	_	_	12	APPO	_	_
14	,	_	,	_	_	13	P	_	_
15	a	_	DT	_	_	17	NMOD	_	_
16	lipid	_	NN	_	_	17	NMOD	_	_
17	regulator	_	NN	_	_	13	APPO	_	_
18	,	_	,	_	_	13	P	_	_
19	and	_	CC	_	_	13	COORD	_	_
20	Dilzem	_	NNP	_	_	19	CONJ	_	_
21	,	_	,	_	_	20	P	_	_
22	a	_	DT	_	_	25	NMOD	_	_
23	calcium	_	NN	_	_	25	NMOD	_	_
24	channel	_	NN	_	_	25	NMOD	_	_
25	blocker	_	NN	_	_	20	APPO	_	_
26	.	_	.	_	_	5	P	_	_

1	World-wide	_	JJ	_	_	2	NMOD	_	_
2	sales	_	NNS	_	_	24	SBJ	_	_
3	of	_	IN	_	_	2	NMOD	_	_
4	Warner-Lambert	_	NNP	_	_	8	NMOD	_	_
5	's	_	POS	_	_	4	SUFFIX	_	_
6	non-prescription	_	JJ	_	_	8	NMOD	_	_
7	health-care	_	NN	_	_	8	NMOD	_	_
8	products	_	NNS	_	_	3	PMOD	_	_
9	,	_	,	_	_	8	P	_	_
10	such	_	JJ	_	_	11	DEP	_	_
11	as	_	IN	_	_	8	NMOD	_	_
12	Halls	_	NNP	_	_	14	NMOD	_	_
13	cough	_	NN	_	_	14	NMOD	_	_
14	tablets	_	NNS	_	_	11	PMOD	_	_
15	,	_	,	_	_	14	P	_	_
16	Rolaids	_	NNP	_	_	17	NMOD	_	_
17	antacid	_	NN	_	_	14	COORD	_	_
18	,	_	,	_	_	17	P	_	_
19	and	_	CC	_	_	17	COORD	_	_
20	Lubriderm	_	NNP	_	_	22	NMOD	_	_
21	skin	_	NN	_	_	22	NMOD	_	_
22	lotion	_	NN	_	_	19	CONJ	_	_
23	,	_	,	_	_	8	P	_	_
24	increased	_	VBD	_	_	0	ROOT	_	_
25	3	_	CD	_	_	26	NMOD	_	_
26	%	_	NN	_	_	24	EXT	_	_
27	to	_	TO	_	_	24	DIR	_	_
28	$	_	$	_	_	27	PMOD	_	_
29	362	_	CD	_	_	28	DEP	_	_
30	million	_	CD	_	_	28	DEP	_	_
31	in	_	IN	_	_	24	TMP	_	_
32	the	_	DT	_	_	34	NMOD	_	_
33	third	_	JJ	_	_	34	NMOD	_	_
34	quarter	_	NN	_	_	31	PMOD	_	_
35	;	_	:	_	_	24	P	_	_
36	U.S.	_	NNP	_	_	37	NMOD	_	_
37	sales	_	NNS	_	_	38	SBJ	_	_
38	rose	_	VBD	_	_	24	COORD	_	_
39	5	_	CD	_	_	40	NMOD	_	_
40	%	_	NN	_	_	38	EXT	_	_
41	.	_	.	_	_	24	P	_	_

1	Confectionery	_	JJ	_	_	3	NMOD	_	_
2	products	_	NNS	_	_	3	NMOD	_	_
3	sales	_	NNS	_	_	5	SBJ	_	_
4	also	_	RB	_	_	5	ADV	_	_
5	had	_	VBD	_	_	0	ROOT	_	_
6	strong	_	JJ	_	_	7	NMOD	_	_
7	growth	_	NN	_	_	5	OBJ	_	_
8	in	_	IN	_	_	5	TMP	_	_
9	the	_	DT	_	_	10	NMOD	_	_
10	quarter	_	NN	_	_	8	PMOD	_	_
11	.	_	.	_	_	5	P	_	_

1	World-wide	_	JJ	_	_	2	NMOD	_	_
2	sales	_	NNS	_	_	18	SBJ	_	_
3	of	_	IN	_	_	2	NMOD	_	_
4	Trident	_	NNP	_	_	5	NMOD	_	_
5	gum	_	NN	_	_	3	PMOD	_	_
6	,	_	,	_	_	5	P	_	_
7	Certs	_	NNP	_	_	9	NMOD	_	_
8	breath	_	NN	_	_	9	NMOD	_	_
9	mints	_	NNS	_	_	5	COORD	_	_
10	,	_	,	_	_	9	P	_	_
11	and	_	CC	_	_	9	COORD	_	_
12	Clorets	_	NNP	_	_	13	NMOD	_	_
13	gum	_	NN	_	_	11	CONJ	_	_
14	and	_	CC	_	_	13	COORD	_	_
15	breath	_	NN	_	_	16	NMOD	_	_
16	mints	_	NNS	_	_	14	CONJ	_	_
17	,	_	,	_	_	5	P	_	_
18	increased	_	VB	_	_	0	ROOT	_	_
19	12	_	CD	_	_	20	NMOD	_	_
20	%	_	NN	_	_	18	EXT	_	_
21	to	_	TO	_	_	18	DIR	_	_
22	$	_	$	_	_	21	PMOD	_	_
23	277	_	CD	_	_	22	DEP	_	_
24	million	_	CD	_	_	22	DEP	_	_
25	.	_	.	_	_	18	P	_	_

1	Warner-Lambert	_	NNP	_	_	2	NMOD	_	_
2	shares	_	NNS	_	_	3	SBJ	_	_
3	closed	_	VBD	_	_	0	ROOT	_	_
4	at	_	IN	_	_	3	ADV	_	_
5	$	_	$	_	_	4	PMOD	_	_
6	109.50	_	CD	_	_	5	NMOD	_	_
7	a	_	DT	_	_	8	NMOD	_	_
8	share	_	NN	_	_	5	ADV	_	_
9	,	_	,	_	_	3	P	_	_
10	up	_	IN	_	_	3	ADV	_	_
11	$	_	$	_	_	10	AMOD	_	_
12	1.50	_	CD	_	_	11	NMOD	_	_
13	,	_	,	_	_	3	P	_	_
14	in	_	IN	_	_	3	LOC	_	_
15	Big	_	NNP	_	_	18	NMOD	_	_
16	Board	_	NNP	_	_	18	NMOD	_	_
17	composite	_	JJ	_	_	18	NMOD	_	_
18	trading	_	NN	_	_	14	PMOD	_	_
19	yesterday	_	NN	_	_	3	TMP	_	_
20	.	_	.	_	_	3	P	_	_

1	Eli	_	NNP	_	_	2	NAME	_	_
2	Lilly	_	NNP	_	_	0	ROOT	_	_
3	&	_	CC	_	_	2	COORD	_	_
4	Co	_	NNP	_	_	3	CONJ	_	_
5	.	_	.	_	_	4	P	_	_

1	Lilly	_	NNP	_	_	2	SBJ	_	_
2	attributed	_	VBD	_	_	0	ROOT	_	_
3	record	_	NN	_	_	4	NMOD	_	_
4	third-quarter	_	JJ	_	_	2	OBJ	_	_
5	and	_	CC	_	_	4	COORD	_	_
6	nine-month	_	JJ	_	_	7	NMOD	_	_
7	results	_	NNS	_	_	5	CONJ	_	_
8	to	_	TO	_	_	2	ADV	_	_
9	world-wide	_	JJ	_	_	10	NMOD	_	_
10	gains	_	NNS	_	_	8	PMOD	_	_
11	for	_	IN	_	_	10	NMOD	_	_
12	pharmaceuticals	_	NNS	_	_	11	PMOD	_	_
13	,	_	,	_	_	12	P	_	_
14	medical	_	JJ	_	_	15	NMOD	_	_
15	instruments	_	NNS	_	_	12	COORD	_	_
16	and	_	CC	_	_	15	COORD	_	_
17	plant-science	_	NN	_	_	18	NMOD	_	_
18	products	_	NNS	_	_	16	CONJ	_	_
19	despite	_	IN	_	_	10	NMOD	_	_
20	poor	_	JJ	_	_	22	NMOD	_	_
21	exchange	_	NN	_	_	22	NMOD	_	_
22	rates	_	NNS	_	_	19	PMOD	_	_
23	for	_	IN	_	_	22	NMOD	_	_
24	the	_	DT	_	_	25	NMOD	_	_
25	dollar	_	NN	_	_	23	PMOD	_	_
26	that	_	WDT	_	_	27	SBJ	_	_
27	slowed	_	VBD	_	_	22	NMOD	_	_
28	sales	_	NNS	_	_	27	OBJ	_	_
29	abroad	_	RB	_	_	28	LOC	_	_
30	.	_	.	_	_	2	P	_	_

1	Earnings	_	NNS	_	_	2	SBJ	_	_
2	continued	_	VBD	_	_	0	ROOT	_	_
3	to	_	TO	_	_	2	OPRD	_	_
4	pace	_	VB	_	_	3	IM	_	_
5	sales	_	NNS	_	_	4	OBJ	_	_
6	because	_	IN	_	_	2	PRP	_	_
7	of	_	IN	_	_	6	DEP	_	_
8	a	_	DT	_	_	11	NMOD	_	_
9	lower	_	JJR	_	_	11	NMOD	_	_
10	tax	_	NN	_	_	11	NMOD	_	_
11	rate	_	NN	_	_	6	PMOD	_	_
12	,	_	,	_	_	11	P	_	_
13	profit	_	NN	_	_	11	COORD	_	_
14	from	_	IN	_	_	13	NMOD	_	_
15	the	_	DT	_	_	16	NMOD	_	_
16	renegotiation	_	NN	_	_	14	PMOD	_	_
17	of	_	IN	_	_	16	NMOD	_	_
18	the	_	DT	_	_	20	NMOD	_	_
19	debt	_	NN	_	_	20	NMOD	_	_
20	instrument	_	NN	_	_	17	PMOD	_	_
21	received	_	VBN	_	_	20	APPO	_	_
22	from	_	IN	_	_	21	ADV	_	_
23	Faberge	_	NNP	_	_	22	PMOD	_	_
24	Inc.	_	NNP	_	_	23	POSTHON	_	_
25	in	_	IN	_	_	21	ADV	_	_
26	connection	_	NN	_	_	25	PMOD	_	_
27	with	_	IN	_	_	26	NMOD	_	_
28	Lilly	_	NNP	_	_	30	NMOD	_	_
29	's	_	POS	_	_	28	SUFFIX	_	_
30	sale	_	NN	_	_	27	PMOD	_	_
31	of	_	IN	_	_	30	NMOD	_	_
32	Elizabeth	_	NNP	_	_	33	NAME	_	_
33	Arden	_	NNP	_	_	31	PMOD	_	_
34	Inc.	_	NNP	_	_	33	POSTHON	_	_
35	in	_	IN	_	_	30	TMP	_	_
36	1987	_	CD	_	_	35	PMOD	_	_
37	,	_	,	_	_	13	P	_	_
38	and	_	CC	_	_	13	COORD	_	_
39	net	_	JJ	_	_	40	NMOD	_	_
40	proceeds	_	NNS	_	_	38	CONJ	_	_
41	from	_	IN	_	_	40	NMOD	_	_
42	the	_	DT	_	_	43	NMOD	_	_
43	settlement	_	NN	_	_	41	PMOD	_	_
44	of	_	IN	_	_	43	NMOD	_	_
45	patent	_	NN	_	_	46	NMOD	_	_
46	litigation	_	NN	_	_	44	PMOD	_	_
47	at	_	IN	_	_	43	LOC	_	_
48	Lilly	_	NNP	_	_	52	NMOD	_	_
49	's	_	POS	_	_	48	SUFFIX	_	_
50	Hybritech	_	NNP	_	_	52	NMOD	_	_
51	Inc.	_	NNP	_	_	52	NMOD	_	_
52	unit	_	NN	_	_	47	PMOD	_	_
53	.	_	.	_	_	2	P	_	_

1	Third-quarter	_	NN	_	_	2	NMOD	_	_
2	sales	_	NNS	_	_	10	SBJ	_	_
3	of	_	IN	_	_	2	NMOD	_	_
4	the	_	DT	_	_	9	NMOD	_	_
5	Indianapolis	_	NNP	_	_	7	NAME	_	_
6	,	_	,	_	_	7	P	_	_
7	Ind.	_	NNP	_	_	9	LOC	_	_
8	,	_	,	_	_	7	P	_	_
9	company	_	NN	_	_	3	PMOD	_	_
10	rose	_	VBD	_	_	0	ROOT	_	_
11	11	_	CD	_	_	12	NMOD	_	_
12	%	_	NN	_	_	10	EXT	_	_
13	to	_	TO	_	_	10	DIR	_	_
14	$	_	$	_	_	13	PMOD	_	_
15	1.045	_	CD	_	_	14	DEP	_	_
16	billion	_	CD	_	_	14	DEP	_	_
17	from	_	IN	_	_	10	DIR	_	_
18	$	_	$	_	_	17	PMOD	_	_
19	940.6	_	CD	_	_	18	DEP	_	_
20	million	_	CD	_	_	18	DEP	_	_
21	.	_	.	_	_	10	P	_	_

1	Nine-month	_	JJ	_	_	2	NMOD	_	_
2	sales	_	NNS	_	_	3	SBJ	_	_
3	grew	_	VBD	_	_	0	ROOT	_	_
4	12	_	CD	_	_	5	NMOD	_	_
5	%	_	NN	_	_	3	EXT	_	_
6	to	_	TO	_	_	3	DIR	_	_
7	$	_	$	_	_	6	PMOD	_	_
8	3.39	_	CD	_	_	7	DEP	_	_
9	billion	_	CD	_	_	7	DEP	_	_
10	from	_	IN	_	_	3	DIR	_	_
11	$	_	$	_	_	10	PMOD	_	_
12	3.03	_	CD	_	_	11	DEP	_	_
13	billion	_	CD	_	_	11	DEP	_	_
14	a	_	DT	_	_	15	NMOD	_	_
15	year	_	NN	_	_	16	AMOD	_	_
16	earlier	_	RBR	_	_	10	TMP	_	_
17	.	_	.	_	_	3	P	_	_

1	Sales	_	NNS	_	_	8	SBJ	_	_
2	of	_	IN	_	_	1	NMOD	_	_
3	Prozac	_	NNP	_	_	2	PMOD	_	_
4	,	_	,	_	_	3	P	_	_
5	an	_	DT	_	_	6	NMOD	_	_
6	anti-depressant	_	NN	_	_	3	APPO	_	_
7	,	_	,	_	_	3	P	_	_
8	led	_	VBD	_	_	0	ROOT	_	_
9	drug-sales	_	NNS	_	_	10	NMOD	_	_
10	increases	_	NNS	_	_	8	OBJ	_	_
11	.	_	.	_	_	8	P	_	_

1	Higher	_	JJR	_	_	2	NMOD	_	_
2	sales	_	NNS	_	_	11	SBJ	_	_
3	of	_	IN	_	_	2	NMOD	_	_
4	pesticides	_	NNS	_	_	3	PMOD	_	_
5	and	_	CC	_	_	4	COORD	_	_
6	other	_	JJ	_	_	8	NMOD	_	_
7	plant-science	_	NN	_	_	8	NMOD	_	_
8	products	_	NNS	_	_	5	CONJ	_	_
9	more	_	RBR	_	_	11	ADV	_	_
10	than	_	IN	_	_	9	AMOD	_	_
11	offset	_	VBP	_	_	32	OBJ	_	_
12	a	_	DT	_	_	14	NMOD	_	_
13	slight	_	JJ	_	_	14	NMOD	_	_
14	decline	_	NN	_	_	11	OBJ	_	_
15	in	_	IN	_	_	14	LOC	_	_
16	the	_	DT	_	_	17	NMOD	_	_
17	sales	_	NNS	_	_	15	PMOD	_	_
18	of	_	IN	_	_	17	NMOD	_	_
19	animal-health	_	NN	_	_	20	NMOD	_	_
20	products	_	NNS	_	_	18	PMOD	_	_
21	to	_	TO	_	_	11	OPRD	_	_
22	fuel	_	VB	_	_	21	IM	_	_
23	the	_	DT	_	_	24	NMOD	_	_
24	increase	_	NN	_	_	22	OBJ	_	_
25	in	_	IN	_	_	24	LOC	_	_
26	world-wide	_	JJ	_	_	29	NMOD	_	_
27	agricultural	_	JJ	_	_	29	NMOD	_	_
28	product	_	NN	_	_	29	NMOD	_	_
29	sales	_	NNS	_	_	25	PMOD	_	_
30	,	_	,	_	_	32	P	_	_
31	Lilly	_	NNP	_	_	32	SBJ	_	_
32	said	_	VBD	_	_	0	ROOT	_	_
33	.	_	.	_	_	32	P	_	_

1	Advanced	_	NNP	_	_	3	NAME	_	_
2	Cardiovascular	_	NNP	_	_	3	NAME	_	_
3	Systems	_	NNPS	_	_	10	SBJ	_	_
4	Inc.	_	NNP	_	_	3	POSTHON	_	_
5	and	_	CC	_	_	3	COORD	_	_
6	Cardiac	_	NNP	_	_	9	NMOD	_	_
7	Pacemakers	_	NNPS	_	_	9	NMOD	_	_
8	Inc.	_	NNP	_	_	9	NMOD	_	_
9	units	_	NNS	_	_	5	CONJ	_	_
10	led	_	VBD	_	_	0	ROOT	_	_
11	growth	_	NN	_	_	10	OBJ	_	_
12	in	_	IN	_	_	11	LOC	_	_
13	the	_	DT	_	_	16	NMOD	_	_
14	medical-instrument	_	JJ	_	_	16	NMOD	_	_
15	systems	_	NNS	_	_	16	NMOD	_	_
16	division	_	NN	_	_	12	PMOD	_	_
17	.	_	.	_	_	10	P	_	_

1	Lilly	_	NNP	_	_	2	NMOD	_	_
2	shares	_	NNS	_	_	3	SBJ	_	_
3	closed	_	VBD	_	_	0	ROOT	_	_
4	yesterday	_	NN	_	_	3	TMP	_	_
5	in	_	IN	_	_	3	LOC	_	_
6	composite	_	JJ	_	_	7	NMOD	_	_
7	trading	_	NN	_	_	5	PMOD	_	_
8	on	_	IN	_	_	7	LOC	_	_
9	the	_	DT	_	_	11	NMOD	_	_
10	Big	_	NNP	_	_	11	NAME	_	_
11	Board	_	NNP	_	_	8	PMOD	_	_
12	at	_	IN	_	_	3	ADV	_	_
13	$	_	$	_	_	12	PMOD	_	_
14	62.25	_	CD	_	_	13	NMOD	_	_
15	,	_	,	_	_	3	P	_	_
16	down	_	IN	_	_	3	ADV	_	_
17	12.5	_	CD	_	_	18	NMOD	_	_
18	cents	_	NNS	_	_	16	AMOD	_	_
19	.	_	.	_	_	3	P	_	_

